April 28, 2022 11:56am

ALNY is down -$15.40 or -9.94% to $139.52 – so far and fluctuating

Net loss was -$234.34 M or -$2.00 per share as compared to Q1/21’s $200.29 M or -$1.71 per share, while the cash position was $2.24 B 

Revenue was $137 M, a -10% decrease compared to Q4/21.

Net product revenues increased 38% compared to Q1/21, net revenues from collaborations decreased 38% compared to the first quarter of 2021, primarily due to a decrease in revenue from its collaboration with Regeneron.

GAAP R&D expenses decreased compared to Q1/21, SG&A increased compared to Q1/21.

This quarterly report represents an earnings surprise of -3.63%. A quarter ago, it was expected that this RNA interference drug developer would post a loss of $1.47 per share when it actually produced a loss of $2.16, delivering a surprise of -46.94%. <Zacks>

ALNY shares have lost about 8.6% since the beginning of the year

Over the last four (4) quarters, ALNY has not been able to surpass consensus EPS estimates.


Guidance: The current consensus EPS estimate is -$1.69 on $276.05 M in revenues for the coming quarter and -$6.92 on $1.15 B in revenues for the 2022. <Zacks>